| Keywords: |
cancer chemotherapy; cancer survival; clinical trial; mortality; drug efficacy; antineoplastic agents; note; comparative study; outcome assessment; antineoplastic agent; letter; neoplasm; neoplasms; quality of life; biomedical research; antineoplastic combined chemotherapy protocols; camptothecin; drug effect; cetuximab; cancer research; outcome assessment (health care); irinotecan; monoclonal antibody; colorectal neoplasms; drug cost; economics; drug costs; patient care; antibodies, monoclonal; drug antagonism; colorectal tumor; colon cancer; medical research; drug derivative; clinical research; cost of illness; socioeconomics; drug use; dna topoisomerase; dna topoisomerases, type i; drug industry; health care need; health care availability; investment; money; humans; human; priority journal; value of life
|
